News
-
-
-
COMMUNIQUÉ DE PRESSE
Quantum Biopharma Announces that Sentinel Dosing has Started for the Phase-1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-Ms) in Australia
Quantum BioPharma starts sentinel dosing for Lucid-21-302 trial in multiple sclerosis treatment. Corporate update includes engaging ITG, Buyins, and Stockjock for Investor Relations Activities -
-
-
COMMUNIQUÉ DE PRESSE
Quantum Biopharma (NASDAQ:QNTM) Posts Link on Its Website to Access the Filed Complaint Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
Quantum BioPharma files $700M lawsuit against CIBC, RBC for market manipulation schemes. Press release details legal action and evidence. Law firms Christian Attar and Freedman Normand Friedland LLP to take the case on a contingency basis -
-
-
COMMUNIQUÉ DE PRESSE
Quantum BioPharma (Nasdaq: QNTM) Files a US Federal Lawsuit Against CIBC World Markets, RBC Dominion Securities and Others, Seeking Damages in Excess of $700,000,000 USD, for Possible Stock Price Manipulation/Spoofing
Christian Attar Law Firm and Freedman Normand Friedland LLP, with forensic investigators, uncover multi-year market manipulation scheme by CIBC, RBC, and others causing $700 Million damage to Quantum BioPharma Ltd -
